Jim Cramer Dissects Kimberly-Clark’s Acquisition of Kenvue

KVUE +0.72% KMB -0.14% JNJ +1.05%

Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said:

“Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, Band-Aids, Aveeno, and so many other household names. I think it’s incredibly compelling as Kenvue stock has… near cut in half from where it came public. Of course, there are risks. The Secretary of Health and Human Services has blamed Tylenol for causing autism. But he seems to think kind of everything causes autism.

Pixabay/Public Domain

Kimberly-Clark Corporation (NASDAQ:KMB) manufactures personal care products and provides items such as diapers, wipes, feminine and incontinence care products, and household paper goods. Its brands include Huggies, Kotex, Depend, Kleenex, Scott, and Cottonelle.

While we acknowledge the potential of KMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.